COVID-19: What we’ve done well and what we could or should have done better—the 4 Ps

Jean-Louis Vincent1*, Julia Wendon2, Greg S. Martin3*, Nicole P. Juffermans4,5, Jacques Creteur1 and Maurizio Cecconi6,7

Abstract
The current coronavirus pandemic has impacted heavily on ICUs worldwide. Although many hospitals and healthcare systems had plans in place to manage multiple casualties as a result of major natural disasters or accidents, there was insufficient preparation for the sudden, massive influx of severely ill patients with COVID-19. As a result, systems and staff were placed under immense pressure as everyone tried to optimize patient management. As the pandemic continues, we must apply what we have learned about our response, both good and bad, to improve organization and thus patient care in the future.

Keywords: Coronavirus, Personalization, Clinical trial design, Sepsis, ICU organization, Endotheliopathy, Acute respiratory failure, ICU admission criteria, Ethical decision making

“Study the past if you would define the future” (Confucius)

Introduction
Since the SARS-CoV-2 pandemic first began, strategies to minimize spread of the virus in the community have been employed but often not early, extensive or effective enough to prevent multiple hospitalizations, intensive care unit (ICU) admissions and deaths. Thus, as the pandemic continues, we, as intensivists, need to be constantly evaluating and reevaluating our response, to review what we have learned, what we have accomplished so far, what we have done well and, perhaps more importantly, what we could have done better.

Here we do just that, dividing our thoughts into four broad areas, the 4 Ps: Preparation, Progress, Personalization, and Prioritization (Table 1). This reflection can help us optimize patient care and ICU organization as coronavirus disease (COVID-19) continues to affect thousands of people worldwide, and will also help as we plan for the likely occurrence of similar situations in the future.

Preparation
As we began to realize the likely impact of the pandemic on our healthcare systems and our ICUs in particular, we rapidly began to prepare by converting other areas of the hospital, such as operating rooms and anesthesia recovery units, into temporary ICUs. Although this was necessary given the large numbers of patients requiring intensive care, it was often done at the expense of routine, non-urgent procedures, which likely has led to increased non-COVID morbidity and mortality, the magnitude of which is only beginning to be fully assessed. Available resources were distributed as evenly as possible among units and hospitals to ensure adequate supplies for all [1]. Nurses and doctors, including those still in training, were transferred from other units to work on the ICU, although training of such personnel was often rushed and inadequate. To enhance training, several groups and societies contributed to rapid expansion of online education, including the European Commission and the European Society of Intensive Care Medicine (ESICM) C19_SPACE program (COVID-19 Skills Preparation Course).
developed to help provide better training for healthcare workers not working regularly in intensive care [2], and the Society for Critical Care Medicine’s (SCCM) training for non-ICU clinicians [3].

Using imagination and innovation, new, simple continuous positive airway pressure (CPAP) systems and basic respirators (even car factories started to make some) were developed and constructed, to meet the increased demand for respiratory support. New methods of involving and informing relatives, who were not allowed to visit their loved ones, and of limiting the feelings of loneliness for patients were devised, including employing video calls.

Of course, with hindsight we could, and indeed should, have been better prepared. Methods to ensure sufficient adequately trained personnel, enough appropriately equipped ICU beds, and adequate amounts of material -from personal protective equipment to ventilators- could all have been better planned and potential alternative supply chains already identified. Plans should have been established to enable transport of patients to hospitals in areas of the country that were less badly affected, or even across international borders. Many countries now have a central distribution system in place ensuring an even spread of patients. Importantly, the provision of on-going psychological support for all those involved in the COVID pandemic -staff, patients and families- should have been foreseen and readily available, personalized to individual requirements.

**Table 1** Some of the aspects we have done well and some we could have done better

| Did well | Could have done better |
|----------|------------------------|
| Preparation | Using other areas of the hospital to expand ICU capacity |
| | Increasing resources when still in pre-epidemic period |
| | Providing more psychological support in some centers |
| Progress | Understanding the pathophysiology |
| | Increasing international collaboration |
| | Increasing definitive RCTs on therapeutic interventions in critically ill patients |
| | Decreasing enthusiasm for unproven and theoretical treatments |
| | Increasing research on susceptibility and host response factors |
| Personalization | Rapidly deciphering individual responses and patterns of disease |
| | Individualizing ARDS management |
| | Paying more attention to tissue perfusion |
| | Making greater use of biomarkers to guide therapy |
| Prioritization | Developing guidelines |
| | Discussing ethical uncertainties and optimizing ICU admissions in some centers |
| | Coordinating resources across centers |

Progress

We have made substantial progress in our understanding of the pathophysiological alterations associated with COVID-19, particularly that the disease is not limited to the respiratory tract and altered lung function, but affects all organs. Identification of the associated endotheliopathy and coagulopathy [4] and documentation of the virus in virtually all organs [5] have helped us appreciate that the whole body is involved and not just the lungs. As a result, management has improved substantially with less use of invasive mechanical ventilation and more effective thrombosis prophylaxis. Mortality rates have also decreased, likely as a result of the improved understanding of the disease process and better patient management [6].

However, we may have made more progress in specific treatments if we had explored the effects of (old and) new therapeutic interventions more carefully. With pressure to identify effective treatments and the feeling that something had to be done to help save lives, we tried too many drugs without testing them rigorously. Results from RECOVERY, SOLIDARITY and REMAP-CAP adaptive research platforms have since demonstrated that many of our initial assumptions were wrong and did not bring any benefit [7, 8]. One example is in the early studies on hydroxychloroquine, results of which were published online without going through the usual rigorous, peer review process. The resultant initial enthusiasm for hydroxychloroquine, with its associated media hype and support from leading celebrities and political figures, became an obstacle to performing effective randomized controlled trials of the drug because high patient and family demand for it to be given limited our ability to randomize patients. This publicity also hampered trials assessing other interventions, because of the concern that the use of hydroxychloroquine could add noise to the trial. Another example is the drug remdesivir. Medical and pharmacoeconomic models were massively involved in propagating a therapy that was later shown not to be very effective, at least in severely ill patients [7]. As with many other aspects of management of this pandemic, international collaboration for clinical trials was poor and results could have been improved by using better structured, international platforms already early
in the pandemic. Identification of the benefits of cortico-
steroid administration was one example of a well-run
clinical trial [9]. However, as a result of early publica-
tion of preliminary results from the RECOVERY trial, other
ongoing trials were stopped early, limiting full interpre-
tation of the results from these later trials [10]. Import-
tantly too, there are many other interventions that could
and should be tested. For example, the endotheliopathy/
coagulopathy may represent an excellent indication for
substances like thrombomodulin [11]. There has also not
been enough research on factors that influence suscepti-
bility to severe manifestations of COVID-19 and the host
response [12], although this may still come.

Personalization

COVID-19 is a single disease, but individual responses
can vary from one person to another and over time,
making it a more heterogeneous condition than initially
thought. At the start of the pandemic, a lot of attention
was paid to the development of acute respiratory dis-
tress syndrome (ARDS) in patients with COVID-19,
with standardized respirator management being given
to all patients with acute respiratory failure, before we
realized the respiratory failure can be multifaceted in
these patients, with some having more focal alterations
[13]. Indeed, although ARDS is a common complication
of COVID-19, it is often not severe initially. Neverthe-
less, early in the pandemic, patients sometimes received
excessive positive end-expiratory pressure (PEEP) based
on the severity of alteration in gas exchange, but with
lung alterations that were not diffuse. Perhaps we spent
too much time trying to find differences between COVID
ARDS and non-COVID ARDS, and global differences
in thoraco-pulmonary compliance whereas treatment
should be individualized according to each patient’s spe-
cific respiratory status. Initially too, a focus on avoiding
lung edema led to restrictive fluid therapy with liberal
use of diuretics, when in fact some patients were hypo-
volemic, leading to a high incidence of mesenteric
ischemia and renal injury, and may have benefitted from
fluid administration. Not enough attention was paid to
the alterations in tissue perfusion that require individual
monitoring and management. We understood that treat-
ment of early COVID-19 was likely to be different from
that of later stage disease, but essentially related this to
the severity of the disease and the degree of alteration in
gas exchange.

As with other areas of critical illness, management
of patients with COVID-19 needs to be personalized
to the individual patient. In general terms, treatment is
biphasic, with a focus on antiviral therapies initially, but
immunomodulating strategies in the later phase, when
viral replication is no longer the major issue. As such,
we could have better used biomarkers [14] to identify an
excessive host response, which has sometimes been (mis)
called a ‘cytokine storm’ [15]. Substances such as tocili-
zumab and anakinra may be effective in some subsets
of patients, whereas benefits may not appear in hetero-
geneous groups of patients who have not been carefully
selected. Similarly, better understanding of how to deter-
mine the optimal dose of anticoagulation is needed so
that it can be personalized for individual patients.

Prioritization

The substantial and unexpectedly rapid surge in numbers
of SARS-CoV-2 infected patients needing ICU admission
meant that rapid decisions frequently had to be made
regarding suitability for admission to critical care. Deci-
sion making in this scenario was based largely on the
presence of comorbidities and taking into account patient
preferences. Although age has been widely reported as
among the factors influencing decisions regarding ICU
admission, frailty and life expectancy are more important
than age. Despite publication of guidelines [16–19], the
ways in which units and individuals interpreted the basic
principles varied considerably, often leading to confusion
and distress. To avoid subjective assessments and inequi-
ties, the principle of a lottery or a ‘first come, first served’
principle was sometimes considered [20]. When criti-
cal resources, such as ICU beds and respiratory support
modalities, can be effectively expanded, this is of course
preferable; but, if all critical care resources are fully occu-
pied by patients with a poor prognosis who are less likely
to benefit from intensive care, the resources can no longer
be used to provide life-saving care to other patients with
a greater chance of recovery. The key in such decisions is
to identify the patients who will benefit most, based on
the combination of their physiological reserve, the status
of their acute illness, and their response to therapy. Dif-
ficult decisions about stopping life-sustaining therapies
when patients are continuing to deteriorate despite opti-
mal interventions also have to be reviewed and should be
assessed in the context of physiology, background health
and appropriate ethical frameworks. These decisions are
not just related to the pandemic. Intensivists regularly
need to make such decisions to ensure intensive care
need and supply are balanced. Carefully defined criteria
for ICU admissions and for withholding and withdrawing
life-sustaining therapies should therefore be in place at all
times.

Use of interventions that demand a high level of
care, such as extracorporeal membrane oxygenation
(ECMO), may also need reconsidering when resources
are stretched. Provision of resource intense therapies
to a limited number of patients may need to be bal-
anced against the provision of less advanced care to
more patients [18]. Importantly, care for other conditions requiring ICU capacity must continue for patients presenting as emergencies and also for those requiring complex elective surgery, whose life expectancy will be markedly impacted if there is any significant delay in their treatment. We also need to address the streaming of patients into COVID-positive, emergency and elective care to provide optimal provision and limit nosocomial spread. Prioritization thus applies to COVID and non-COVID patients equally.

Importantly, we have had to learn to accept that, under such demanding conditions and with limited resources (in terms of number and quality), it is not always possible or practical to offer the quality of care we would wish and are used to providing; this is very difficult to accept psychologically, but is the only way to manage the increased patient numbers.

**Conclusion**

As we continue to move through this pandemic, with many countries still challenged by high case numbers and hospitalizations, these aspects of preparation, progress, personalization and prioritization will continue to be discussed and our approach must evolve according to new discoveries and changes in pandemic presentation and patient demographics. There is already much we have learned that will improve the way in which we face the rising numbers of admissions and manage our patients. What we have learned and will learn over the next weeks and months will help us prepare for similar events in the future, will fuel continued progress in disease understanding and management, will encourage us to personalize patient treatment, and will facilitate the difficult decisions to prioritize care when necessary.

**Abbreviations**

ARDS: Acute respiratory distress syndrome; CPAP: Continuous positive airway pressure; ECMO: Extracorporeal membrane oxygenation; ESICM: European Society of Intensive Care Medicine; ICU: Intensive care unit; PEEP: Positive end-expiratory pressure; SCCM: Society of Critical Care Medicine.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

JLV write the first draft. JW, GSM, NPJ, JC, MC critically revised the manuscript. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

JLV is Editor-in-Chief of *Critical Care*. The other authors declare that they have no relevant conflicts of interest.

**Author details**

1. Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium. 2. Department of Critical Care, Kings College Hospital Foundation Trust, London, UK. 3. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 4. Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Centre, Location Academic Medical Centre, Amsterdam, The Netherlands. 5. Department of Intensive Care, OLVG Hospital, Amsterdam, The Netherlands. 6. Department of Anesthesiology and Intensive Care, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy. 7. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

**Received: 26 November 2020 Accepted: 13 January 2021 Published online: 28 January 2021**

**References**

1. Grasso G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020;323(15):1545–6.
2. ESICM. C19_Space Skills Preparation Course. https://www.esicm.org/wp-content/uploads/2020/10/C19_SPACE-2020.pdf. Accessed 29/12/20.
3. SCCM. Critical care for non-ICU clinicians. https://sccm.org/Disaster/COVID19-ResourceResponseCenter. Accessed 29/12/20.
4. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24:253.
5. Remmelink M, De Mendonça R, D’Haene N, De Viguerie G, Lebrun L, et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care. 2020;24:495.
6. Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving survival of critical care patients with Coronavirus Disease 2019 in England: a national cohort study, March to June 2020. Crit Care Med. 2021;49:209–14.
7. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiamoorthy V, Abdool Karim Q, et al. Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2023184.
8. Burki TK. Completion of clinical trials in light of COVID-19. Lancet Respir Med. 2020;8:1178–80.
9. Horby P, Lim WS, Emberson JR, McFadden E, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436.
10. De Backer D, Azoulay E, Vincent JL. Corticosteroids in severe COVID-19: a critical view of the evidence. Crit Care. 2020;24:627.
11. Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET Randomized Clinical Trial. JAMA. 2019;321(3):993–2003.
12. Parco-Castineira E, Clohissey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2020. https://doi.org/10.1038/s41586-020-03065-8.
13. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24:154.
14. Shrestha GS, Paneru HR, Vincent JL. Precision medicine for COVID-19: a call for better clinical trials. Crit Care. 2020;24:282.
15. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233–44.
16. Aziz S, Arabi YM, Alhazzani W, Evans L, Cruden G, Fischkoff K, et al. Managing ICU surge during the COVID-19 crisis: rapid guidelines. Intensive Care Med. 2020;46:1303–25.
17. Emanuel EJ, Persad G, Upshur R, Thorne B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382:2049–55.
18. Vincent JL, Creteur J. Ethical aspects of the COVID-19 crisis: How to deal with an overwhelming shortage of acute beds. Eur Heart J Acute Cardiovasc Care. 2020;9:248–52.
19. White DB, Lo B. A framework for rationing ventilators and critical care beds during the COVID-19 pandemic. JAMA. 2020;323:1773–4.
20. White DB, Angus DC. A proposed lottery system to allocate scarce COVID-19 medications: promoting fairness and generating knowledge. JAMA. 2020;324:329–30.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.